CLARK IAN T 4

What Happened Ian T. Clark, a director of Olema Pharmaceuticals (OLMA), was granted a derivative award covering 29,500 shares on June 18, 2026. The grant is reported on the Form 4 as an acquisition (code A) at $0.00 (i.e., recorded as a stock option/award rather than an open‑market purchase or sale).

Key Details

• Transaction date: 2026-06-18; Report filed: 2026-06-23 (filing was late by one business day).
• Transaction type: Grant/Award (derivative) for 29,500 shares, reported price $0.00.
• Shares owned after transaction: Not disclosed in the filing excerpt.
• Vesting (from footnote): Vesting in 12 equal monthly installments beginning June 18, 2026; any unvested portion vests in full on the issuer’s next annual meeting if not otherwise fully vested, subject to continuous service.
• No 10b5-1 plan, tax withholding, or immediate sale reported in this filing.

Context This was a grant of an equity award (derivative/option) rather than a purchase or sale of stock. Such awards typically serve as compensation and vest over time; they do not by themselves signal an immediate buy or sell by the insider. The late filing is procedural and should be noted but does not, by itself, imply any change in company fundamentals.